Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.
Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P, Nieto V, Otero B, Sánchez-Méndez S, de Frutos VÁ, Andraca L, Barriga P, Benítez Z, Bombas T, Cancelo MJ, Cano A, Branco CC, Correa M, Doval JL, Fasero M, Fiol G, Garello NC, Genazzani AR, Gómez AI, Gómez MÁ, González S, Goulis DG, Guinot M, Hernández LR, Herrero S, Iglesias E, Jurado AR, Lete I, Lubián D, Martínez M, Nieto A, Nieto L, Palacios S, Pedreira M, Pérez-Campos E, Plá MJ, Presa J, Quereda F, Ribes M, Romero P, Roca B, Sánchez-Capilla A, Sánchez-Borrego R, Santaballa A, Santamaría A, Simoncini T, Tinahones F, Calaf J. Mendoza N, et al. Among authors: pla mj. Maturitas. 2022 Dec;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. Epub 2022 Aug 30. Maturitas. 2022. PMID: 36081216
Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review.
Fiol G, Lete I, Nieto L, Santaballa A, Pla MJ, Baquedano L, Calaf J, Coronado P, de la Viuda E, Llaneza P, Otero B, Sánchez-Méndez S, Ramírez I, Mendoza N; “HMT Elegibility Criteria Group”. Fiol G, et al. Among authors: pla mj. J Clin Med. 2023 Aug 12;12(16):5263. doi: 10.3390/jcm12165263. J Clin Med. 2023. PMID: 37629305 Free PMC article. Review.
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
Fernandez-Gonzalez S, Falo C, Pla MJ, Campos M, Ortega-Exposito C, Ortega R, Vicente M, Petit A, Bosch-Schips J, Bajen MT, Reyes G, Martínez E, González-Viguera J, Peñafiel J, Stradella A, Pernas S, Ponce J, Garcia-Tejedor A. Fernandez-Gonzalez S, et al. Among authors: pla mj. Breast Cancer Res Treat. 2024 Apr 18. doi: 10.1007/s10549-024-07274-1. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38635082
Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial).
Garcia-Tejedor A, Ortega-Exposito C, Salinas S, Luzardo-González A, Falo C, Martinez-Pérez E, Pérez-Montero H, Soler-Monsó MT, Bajen MT, Benitez A, Ortega R, Petit A, Guma A, Campos M, Plà MJ, Pernas S, Peñafiel J, Yeste C, Gil-Gil M, Guedea F, Ponce J, Laplana M. Garcia-Tejedor A, et al. Among authors: pla mj. Front Oncol. 2023 Aug 9;13:1184021. doi: 10.3389/fonc.2023.1184021. eCollection 2023. Front Oncol. 2023. PMID: 37621686 Free PMC article.
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A, Falo C, Fernandez-Gonzalez S, Laplana M, Gil-Gil M, Soler-Monso T, Martinez-Perez E, Calvo I, Calpelo H, Bajen MT, Benitez A, Ortega R, Petit A, Guma A, Campos M, Stradella A, Lopez-Ojeda A, Ponce J, Pla MJ, Pernas S. Garcia-Tejedor A, et al. Among authors: pla mj. Breast Cancer Res Treat. 2023 Jun;199(3):445-456. doi: 10.1007/s10549-023-06926-y. Epub 2023 Apr 12. Breast Cancer Res Treat. 2023. PMID: 37043108
Effectiveness and safety of intraoperative radiotherapy (IORT) with low-energy X-rays (INTRABEAM®) for accelerated partial breast irradiation (APBI).
Laplana M, García-Marqueta M, Sánchez-Fernández JJ, Martínez-Pérez E, Pérez-Montero H, Martínez-Montesinos I, Eraso A, Saldaña P, Martín R, Martín MI, Pla MJ, García-Tejedor A, Guedea F. Laplana M, et al. Among authors: pla mj. Clin Transl Oncol. 2022 Sep;24(9):1732-1743. doi: 10.1007/s12094-022-02823-w. Epub 2022 Mar 19. Clin Transl Oncol. 2022. PMID: 35305245
34 results